ZESTAGEN IS COMMITTED TO THE DEVELOPMENT OF NOVEL MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER.

Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90). hsp90 is a validated pharmaceutical target. ehsp90 is implicated in cancer cell motility, migration and metastasis. It is detectable at the surface of several cancer cells but not of normal adult cells. Zestagen's mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors which do not discriminate between the extracellular and intracellular hsp90 pool, Zestagen’s mAbs are predicted to display a superior therapeutic index in cancer patients.

PIPELINE

Zestagen SA develops light chain mAbs against extracellular hsp90, a subset of hsp90 that is purported to facilitate cancer cell motility, migration and metastasis. The antibodies have documented proof-of-efficacy in in vitro assays as well as in preclinical animal models of cancer.

Learn More

ABOUT US

ZestagenZestagen SA is a Swiss biotechnology company developing novel monoclonal antibodies for the treatment of various cancer indications. 

Learn More

ZESTAGEN AT A SNAPSHOT

Zestagen SA is currently seeking investors to advance the development of its monoclonal antibodies against extracellular hsp90 in cancer.

Download this pdf for a company summary and contact information.